Warner-Lambert's Cognex
Executive Summary
Firm expects to file NDA for Cognex (tacrine or THA) as a treatment for Alzheimer's Disease in June 1990. The drug is currently being evaluated by the National Institutes of Health in 300 Alzheimer's patients at 17 centers.